Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance.
Fiche publication
Date publication
janvier 2021
Journal
International heart journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Girerd N, Aubry M, Lantelme P, Huttin O, Rossignol P
Lien Pubmed
Résumé
Intravenous mineralocorticoid receptor antagonists (MRAs) have been used in some centers for decades to reduce the risk of hypokalemia and boost diuresis in acutely decompensated heart failure (ADHF). We report the well-tolerated use of intravenous MRAs as a rescue procedure in 3 patients admitted for ADHF with important diuretic resistance. Undertaking trials evaluating the effect of this therapeutic strategy in ADHF could represent a promising avenue.
Mots clés
Cardiac edema, Cardiovascular diseases, Congestive heart failure, Dyspnea, Furosemide, Potassium canrenoate
Référence
Int Heart J. 2021 Jan 16;: